Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Profit After Tax (2020 - 2026)

Pharvaris' (PHVS) quarterly Profit After Tax came in at -$45.9 million in Q1 2026, up 5.85% YoY from -$43.4 million in Q1 2025, and up 15.65% on a QoQ basis from -$54.4 million in Q4 2025.

Analysis

Pharvaris (PHVS) Profit After Tax (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Profit After Tax data on file, last reported at -$45.9 million in Q1 2026.

  • Quarterly Profit After Tax rose 5.85% year-over-year to -$45.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195.2 million (down 19.23% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
  • Profit After Tax climbed to -$45.9 million in Q1 2026, from -$54.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$8.6 million in Q3 2022 to a low of -$54.4 million in Q4 2025.
  • A 5-year average of -$34.0 million and a median of -$35.2 million in 2023 frame the typical range for Profit After Tax.
  • Annual changes were most pronounced in 2022 — Profit After Tax increased 26.44% — and 2023, when it plunged 200.18%.
  • Tracing PHVS's Profit After Tax over 5 years: stood at -$40.0 million in 2022, then rose by 11.89% to -$35.2 million in 2023, then declined by 5.42% to -$37.1 million in 2024, then tumbled by 46.47% to -$54.4 million in 2025, then rose by 15.65% to -$45.9 million in 2026.
  • The last three Profit After Tax figures came in at -$45.9 million (Q1 2026), -$54.4 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -16.62 Mn
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 -55.61 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -55.61 Mn
Mar 31, 2026 -45.89 Mn
Dec 31, 2025 -54.41 Mn
Sep 30, 2025 -43.42 Mn
Jun 30, 2025 -51.48 Mn
Mar 31, 2025 -48.75 Mn
Dec 31, 2024 -37.15 Mn
Sep 30, 2024 -45.81 Mn
Jun 30, 2024 -32.02 Mn
Mar 31, 2024 -30.44 Mn
Dec 31, 2023 -35.23 Mn
Sep 30, 2023 -25.69 Mn
Jun 30, 2023 -23,845.13 Bn
Mar 31, 2023 -24.29 Mn
Dec 31, 2022 -39.99 Mn
Sep 30, 2022 -8.56 Mn
Jun 30, 2022 -13,467.40 Bn
Mar 31, 2022 -17.99 Mn
Dec 31, 2021 -14.12 Mn
Sep 30, 2021 -10.78 Mn